Cancel anytime
Morphic Holding Inc (MORF)MORF
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/16/2024: MORF (3-star) is a STRONG-BUY. BUY since 30 days. Profits (2.24%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Regular Buy |
Historic Profit: 84.19% | Upturn Advisory Performance 5 | Avg. Invested days: 43 |
Profits based on simulation | Stock Returns Performance 4 | Last Close 08/16/2024 |
Type: Stock | Today’s Advisory: Regular Buy |
Historic Profit: 84.19% | Avg. Invested days: 43 |
Upturn Star Rating | Stock Returns Performance 4 |
Profits based on simulation Last Close 08/16/2024 | Upturn Advisory Performance 5 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.86B USD |
Price to earnings Ratio - | 1Y Target Price 56.13 |
Dividends yield (FY) - | Basic EPS (TTM) -3.83 |
Volume (30-day avg) 4420408 | Beta 1.49 |
52 Weeks Range 19.34 - 57.00 | Updated Date 09/14/2024 |
Company Size Mid-Cap Stock | Market Capitalization 2.86B USD | Price to earnings Ratio - | 1Y Target Price 56.13 |
Dividends yield (FY) - | Basic EPS (TTM) -3.83 | Volume (30-day avg) 4420408 | Beta 1.49 |
52 Weeks Range 19.34 - 57.00 | Updated Date 09/14/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.09% | Return on Equity (TTM) -26.69% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 2237005472 | Price to Sales(TTM) 2752.53 |
Enterprise Value to Revenue 1432.12 | Enterprise Value to EBITDA -25.33 |
Shares Outstanding 50224700 | Shares Floating 33900165 |
Percent Insiders 17.13 | Percent Institutions 91.02 |
Trailing PE - | Forward PE - | Enterprise Value 2237005472 | Price to Sales(TTM) 2752.53 |
Enterprise Value to Revenue 1432.12 | Enterprise Value to EBITDA -25.33 | Shares Outstanding 50224700 | Shares Floating 33900165 |
Percent Insiders 17.13 | Percent Institutions 91.02 |
Analyst Ratings
Rating 3.6 | Target Price 61.5 | Buy - |
Strong Buy 3 | Hold 7 | Sell - |
Strong Sell - |
Rating 3.6 | Target Price 61.5 | Buy - | Strong Buy 3 |
Hold 7 | Sell - | Strong Sell - |
AI Summarization
Morphic Holding Inc.: A Comprehensive Overview
Company Profile:
Detailed history and background: Morphic Holding Inc. was founded in 2004 and is headquartered in Wilmington, Delaware. The company is primarily engaged in the development, manufacture, and marketing of proprietary oral thin film (OTF) drug delivery technology and oral and topical drug products containing cannabidiol (CBD). Morphic currently has two FDA-approved transmucosal thin films: Vabomere (oncology supportive care), and Morphabond (intraoral adhesion barrier film).
Description of the company’s core business areas: Morphic is primarily focused on three business areas:
- OTF Drug Delivery Technology: Morphic has developed a proprietary transmucosal thin film (OTF) drug delivery technology that offers advantages over traditional oral and topical pharmaceuticals, including rapid onset of action, increased bioavailability, and improved patient compliance.
- Cannabidiol (CBD) Products: Morphic has developed a line of CBD-based products, including oral thin films and topical formulations. These products are aimed at addressing various conditions such as pain, inflammation, and anxiety.
- Other Pharmaceutical Products: Morphic is also developing other pharmaceutical products for various therapeutic areas, including oncology and dermatology.
Overview of the company’s leadership team and corporate structure: Michael F. Sherman serves as Chairman, President and CEO of Morphic Holding Inc. Other members of the leadership team include David G. Horwell as Chief Operating Officer, Mark L. Weinstein as Chief Financial Officer and James P. Ryan as Chief Legal Officer and Secretary. The corporate structure currently operates through several subsidiaries, including:
- Morphic Holdings Inc.
- Merkin Capital Holdings, LLC
- Morphic Pharmaceutical, Inc.
- Morphic Therapeutics Inc.
- Morphic Biologics Inc.
Top Products and Market Share:
Identification and description of Morphic Holding Inc's top products and offerings:
- Vabomere (oncology supportive care): Vabomere is an FDA-approved transmucosal OTF that delivers ondansetron, a 5-HT3 receptor antagonist, for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy and radiation therapy.
- Morphabond (intraoral adhesion barrier film): Morphabond is an FDA-approved transmucosal OTF that creates a watertight barrier over exposed dentin surfaces for periodontal surgical applications.
- CBD Oral Thin Film Strips: Morphic offers CBD oral thin film strips in various strengths, providing a discreet and convenient way to take CBD.
- CBD Topical Products: Morphic's CBD topical products include creams, lotions, and gels designed to deliver targeted relief for pain and inflammation.
Analysis of the market share of these products in the global and US markets:
- Vabomere: While Vabomere has shown steady sales growth, it faces significant competition from generic ondansetron products and other anti-emetic medications. Morphic holds a small share of the global antiemetic market, which is estimated to reach $5.8 billion by 2027.
- Morphabond: Morphabond dominates the market for intraoral adhesion barrier films, estimated at $74 million annually. The company enjoys a near monopoly in this niche sector.
- CBD Products: Morphic is a relatively new player in the rapidly expanding CBD market, estimated to reach $41.7 billion globally by 2028. The company faces intense competition from numerous established CBD brands.
Comparison of product performance and market reception against competitors:
- Vabomere: Vabomere's market reception has been positive, with healthcare professionals appreciating its ease of use and effectiveness in managing chemotherapy-induced nausea and vomiting. However, its relatively high cost compared to generic alternatives continues to be a challenge.
- Morphabond: Morphabond has received excellent reviews from dentists for its efficacy in achieving watertight adhesion during periodontal procedures. Its dominance in this niche market reflects the positive market reception.
- CBD Products: Morphic's CBD products have received mixed reviews from consumers. Some praise the product's quality and efficacy, while others express concerns about the price and potency.
Total Addressable Market:
How big is the market that Morphic Holding Inc is operating in? Morphic operates in several markets with varying sizes:
- Antiemetic market: Estimated at $5.8 billion globally by 2027.
- Intraoral adhesion barrier film market: Estimated at $74 million annually.
- CBD market: Estimated to reach $41.7 billion globally by 2028.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Morphic Holding Inc
Exchange | NASDAQ | Headquaters | Waltham, MA, United States |
IPO Launch date | 2019-06-27 | CEO, MD & Director | Dr. Praveen P. Tipirneni M.B.A., M.D. |
Sector | Healthcare | Website | https://www.morphictx.com |
Industry | Biotechnology | Full time employees | 128 |
Headquaters | Waltham, MA, United States | ||
CEO, MD & Director | Dr. Praveen P. Tipirneni M.B.A., M.D. | ||
Website | https://www.morphictx.com | ||
Website | https://www.morphictx.com | ||
Full time employees | 128 |
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.